Literature DB >> 17345710

[Experimental investigation of CD133 as a putative marker of tumor-initiating cell in laryngeal carcinoma].

Xu-dong Wei1, Liang Zhou, Lei Cheng, Jie Tian.   

Abstract

OBJECTIVE: To detect the expression of CD133 in human larynx tumor cell line, Hep-2 cell line and observe proliferation and differentiation ability of CD133+ groups in vitro.
METHODS: Immunocytochemical staining and flow cytometry were used to detect the expression of putative tumor-initiating cell marker CD133 in Hep-2 cell line, and the selective technique of immunomagnetic beads was applied to purify CD133 positive cells. CD133+ tumor cells were cultured and their ability of proliferation and differentiation were observed in vitro.
RESULTS: Only 3. 22% of cells in Hep-2 cell line expressed CD133. In serum-free RPMI1640, On days 3, 5 and 7, their UV absorption were 0. 320,0. 370 and 0. 558 respectively. Compared with CD133 - cells and control Hep-2 cells, CD133 + cells demonstrated increased proliferation capacity. The proportion of CD133+ cells decreased in culture as days passed. In twelve days of culture, the percentage of CD133+ cells decreased from 90. 88% to 4. 53 %.
CONCLUSIONS: CD133 was one of makers for tumor-initiating cell of human laryngeal carcinoma, Hep-2 cell line. Its identification would provide a helpful tool to investigate the tumorigenic process of human laryngeal carcinoma and to develop targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17345710

Source DB:  PubMed          Journal:  Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi        ISSN: 1673-0860


  2 in total

1.  Study on the chemotherapeutic effect and mechanism of cucurbitacin E on laryngeal cancer stem cells.

Authors:  Xuelian Jiang; Binjuan Ma; Xudong Wei; Xiaoyan Xu; Jiyan Cao; Jingyue Zhang
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-03-24

2.  Role of CD133+ cells in tongue squamous carcinomas: Characteristics of 'stemness' in vivo and in vitro.

Authors:  Kai Wang; Xiao-Kang Zhou; Min Wu; Fei-Wu Kang; Zuo-Lin Wang; Yan Zhu
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.